Davis Polk is advising JP Morgan Securities LLC and Lazard as financial advisers to Aimmune Therapeutics in connection with its $2.6 billion sale to Sociétés des Produits Nestlé, S.A., a wholly owned subsidiary of Nestlé S.A. The transaction is expected to be completed in the fourth quarter of 2020, subject to customary closing conditions.

Aimmune Therapeutics, Inc. is a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies. With a mission to improve the lives of people with food allergies, Aimmune is developing and commercializing oral treatments for potentially life-threatening food allergies. Sociétés des Produits Nestlé, S.A. is a part of Nestlé Health Science. Nestlé Health Science, a global business unit of Nestlé S.A., is a globally recognized leader in the field of nutritional science.

The Davis Polk corporate team includes partners Phillip R. Mills and Alan F. Denenberg and associate Daisy Wu. Members of the Davis Polk team are based in the New York and Northern California offices.

Copy link to share post